Literature DB >> 22752853

GBM secretome induces transient transformation of human neural precursor cells.

Chitra Venugopal1, X Simon Wang, Branavan Manoranjan, Nicole McFarlane, Sara Nolte, Meredith Li, Naresh Murty, K W Michael Siu, Sheila K Singh.   

Abstract

Glioblastoma (GBM) is the most aggressive primary brain tumor in humans, with a uniformly poor prognosis. The tumor microenvironment is composed of both supportive cellular substrates and exogenous factors. We hypothesize that exogenous factors secreted by brain tumor initiating cells (BTICs) could predispose normal neural precursor cells (NPCs) to transformation. When NPCs are grown in GBM-conditioned media, and designated as "tumor-conditioned NPCs" (tcNPCs), they become highly proliferative and exhibit increased stem cell self-renewal, or the unique ability of stem cells to asymmetrically generate another stem cell and a daughter cell. tcNPCs also show an increased transcript level of stem cell markers such as CD133 and ALDH and growth factor receptors such as VEGFR1, VEGFR2, EGFR and PDGFRα. Media analysis by ELISA of GBM-conditioned media reveals an elevated secretion of growth factors such as EGF, VEGF and PDGF-AA when compared to normal neural stem cell-conditioned media. We also demonstrate that tcNPCs require prolonged or continuous exposure to the GBM secretome in vitro to retain GBM BTIC characteristics. Our in vivo studies reveal that tcNPCs are unable to form tumors, confirming that irreversible transformation events may require sustained or prolonged presence of the GBM secretome. Analysis of GBM-conditioned media by mass spectrometry reveals the presence of secreted proteins Chitinase-3-like 1 (CHI3L1) and H2A histone family member H2AX. Collectively, our data suggest that GBM-secreted factors are capable of transiently altering normal NPCs, although for retention of the transformed phenotype, sustained or prolonged secretome exposure or additional transformation events are likely necessary.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22752853     DOI: 10.1007/s11060-012-0917-1

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  49 in total

1.  CHI3L1 (YKL-40) is expressed in human gliomas and regulates the invasion, growth and survival of glioma cells.

Authors:  Bo Mi Ku; Yeon Kyung Lee; Jinhyun Ryu; Joo Yeon Jeong; Jungil Choi; Keyoung Mi Eun; Hye Young Shin; Dong Gyu Kim; Eun Mi Hwang; Jae Cheal Yoo; Jae-Yong Park; Gu Seob Roh; Hyun Joon Kim; Gyeong Jae Cho; Wan Sung Choi; Sun Ha Paek; Sang Soo Kang
Journal:  Int J Cancer       Date:  2011-03-15       Impact factor: 7.396

2.  Search for cancer markers from endometrial tissues using differentially labeled tags iTRAQ and cICAT with multidimensional liquid chromatography and tandem mass spectrometry.

Authors:  Leroi DeSouza; Georg Diehl; Mary Joe Rodrigues; Jingzhong Guo; Alexander D Romaschin; Terence J Colgan; K W Michael Siu
Journal:  J Proteome Res       Date:  2005 Mar-Apr       Impact factor: 4.466

3.  Identification of candidate biomarker proteins released by human endometrial and cervical cancer cells using two-dimensional liquid chromatography/tandem mass spectrometry.

Authors:  Hongyan Li; Leroi V DeSouza; Shaun Ghanny; Wei Li; Alexander D Romaschin; Terence J Colgan; K W Michael Siu
Journal:  J Proteome Res       Date:  2007-05-25       Impact factor: 4.466

Review 4.  Integrins: a family of cell surface receptors.

Authors:  R O Hynes
Journal:  Cell       Date:  1987-02-27       Impact factor: 41.582

5.  Transplacental production with ethylnitrosourea of neoplasms of the nervous system in Sprague-Dawley rats.

Authors:  A Koestner; J A Swenberg; W Wechsler
Journal:  Am J Pathol       Date:  1971-04       Impact factor: 4.307

6.  YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas.

Authors:  Adília Hormigo; Bin Gu; Sasan Karimi; Elyn Riedel; Katherine S Panageas; Mark A Edgar; Meena K Tanwar; Jasti S Rao; Martin Fleisher; Lisa M DeAngelis; Eric C Holland
Journal:  Clin Cancer Res       Date:  2006-10-01       Impact factor: 12.531

7.  Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma.

Authors:  Janice M Nigro; Anjan Misra; Li Zhang; Ivan Smirnov; Howard Colman; Chandi Griffin; Natalie Ozburn; Mingang Chen; Edward Pan; Dimpy Koul; W K Alfred Yung; Burt G Feuerstein; Kenneth D Aldape
Journal:  Cancer Res       Date:  2005-03-01       Impact factor: 12.701

8.  Histone 2A, a heteromorphous family of eight protein species.

Authors:  M H West; W M Bonner
Journal:  Biochemistry       Date:  1980-07-08       Impact factor: 3.162

9.  Structural comparisons of mouse histones 2A.X and 2A.Z with 2A.1 and 2A.2.

Authors:  M H West; W M Bonner
Journal:  Comp Biochem Physiol B       Date:  1983

Review 10.  Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics?

Authors:  Emmanuelle Passegué; Catriona H M Jamieson; Laurie E Ailles; Irving L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-22       Impact factor: 11.205

View more
  15 in total

1.  Inflammatory cytokines, interleukin-1 beta and tumor necrosis factor-alpha, upregulated in glioblastoma multiforme, raise the levels of CRYAB in exosomes secreted by U373 glioma cells.

Authors:  Rajshekhar A Kore; Edathara C Abraham
Journal:  Biochem Biophys Res Commun       Date:  2014-09-26       Impact factor: 3.575

Review 2.  Epidermal growth factor signaling in transformed cells.

Authors:  Stephan Lindsey; Sigrid A Langhans
Journal:  Int Rev Cell Mol Biol       Date:  2014-11-18       Impact factor: 6.813

3.  The Relevance of Circadian Clocks to Stem Cell Differentiation and Cancer Progression.

Authors:  Astha Malik; Shreya Nalluri; Arpan De; Dilshan Beligala; Michael E Geusz
Journal:  NeuroSci       Date:  2022-03-29

4.  From glioblastoma to endothelial cells through extracellular vesicles: messages for angiogenesis.

Authors:  Ilaria Giusti; Simona Delle Monache; Marianna Di Francesco; Patrizia Sanità; Sandra D'Ascenzo; Giovanni Luca Gravina; Claudio Festuccia; Vincenza Dolo
Journal:  Tumour Biol       Date:  2016-07-22

5.  BMI1 is a therapeutic target in recurrent medulloblastoma.

Authors:  David Bakhshinyan; Chitra Venugopal; Ashley A Adile; Neha Garg; Branavan Manoranjan; Robin Hallett; Xin Wang; Sujeivan Mahendram; Parvez Vora; Thusyanth Vijayakumar; Minomi Subapanditha; Mohini Singh; Michelle Masayo Kameda-Smith; Maleeha Qazi; Nicole McFarlane; Aneet Mann; Olufemi A Ajani; Blake Yarascavitch; Vijay Ramaswamy; Hamza Farooq; Sorana Morrissy; Liangxian Cao; Nadiya Sydorenko; Ramil Baiazitov; Wu Du; Josephine Sheedy; Marla Weetall; Young-Choon Moon; Chang-Sun Lee; Jacek M Kwiecien; Kathleen H Delaney; Brad Doble; Yoon-Jae Cho; Siddhartha Mitra; David Kaplan; Michael D Taylor; Thomas W Davis; Sheila K Singh
Journal:  Oncogene       Date:  2018-10-22       Impact factor: 9.867

6.  Interleukin-1-induced changes in the glioblastoma secretome suggest its role in tumor progression.

Authors:  Leonid Tarassishin; Jihyeon Lim; D Brent Weatherly; Ruth H Angeletti; Sunhee C Lee
Journal:  J Proteomics       Date:  2014-02-04       Impact factor: 4.044

7.  Proteomic profiling of the tumor microenvironment: recent insights and the search for biomarkers.

Authors:  Sam Hanash; Mark Schliekelman
Journal:  Genome Med       Date:  2014-02-27       Impact factor: 11.117

8.  Transfer of malignant trait to immortalized human cells following exposure to human cancer serum.

Authors:  Mohamed Abdouh; Shufeng Zhou; Vincenzo Arena; Manuel Arena; Anthoula Lazaris; Ronald Onerheim; Peter Metrakos; Goffredo Orazio Arena
Journal:  J Exp Clin Cancer Res       Date:  2014-09-30

9.  TrkB-containing exosomes promote the transfer of glioblastoma aggressiveness to YKL-40-inactivated glioblastoma cells.

Authors:  Sandra Pinet; Barbara Bessette; Nicolas Vedrenne; Aurélie Lacroix; Laurence Richard; Marie-Odile Jauberteau; Serge Battu; Fabrice Lalloué
Journal:  Oncotarget       Date:  2016-08-02

10.  Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide.

Authors:  Joanna Triscott; Cathy Lee; Kaiji Hu; Abbas Fotovati; Rachel Berns; Mary Pambid; Margaret Luk; Richard E Kast; Esther Kong; Eric Toyota; Stephen Yip; Brian Toyota; Sandra E Dunn
Journal:  Oncotarget       Date:  2012-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.